-

06:07:56 AM

GANX Stock News

GANX - Gain Therapeutics Inc

05/18/22 8:00 AM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule

RHEA-AI

neutral

05/16/22 4:05 PM

Nasdaq : GANX

earningslow float

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Second half of 2023 and a Strong

RHEA-AI

neutral

05/11/22 9:30 AM

Nasdaq : GANX

clinical triallow float

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the

RHEA-AI

neutral

05/06/22 8:00 AM

Nasdaq : GANX

clinical triallow float

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company applying its proprietary computational

RHEA-AI

neutral

04/26/22 5:18 PM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform,

RHEA-AI

neutral

04/12/22 1:00 PM

Nasdaq : GANX

low float

Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a

RHEA-AI

neutral

03/29/22 8:00 AM

Nasdaq : GANX

low float

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming

RHEA-AI

neutral

03/24/22 8:00 AM

Nasdaq : GANX

earningslow float

Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update

- Compelling preclinical data presented on lead program GBA1 Parkinson’s Disease at multiple scientific conferences

RHEA-AI

neutral

03/15/22 8:00 AM

Nasdaq : GANX

low float

Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference

Study results provide additional validation that SEE-Tx platform identifies brain-penetrant small molecules ideally suited for CNS diseases caused by protein misfolding Demonstration of in vitro and in vivo functional efficacy in neurodegenerative disease with GCase causality First demonstration of

RHEA-AI

positive

03/01/22 8:00 AM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences

Gain Therapeutics, Inc.

RHEA-AI

neutral